Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.